Patents by Inventor Gerhard Stauder

Gerhard Stauder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition
    Publication number: 20070155685
    Abstract: The present invention is related to pharmaceutical compositions for the inhibition of metastases and treatment of cancer such as bladder carcinoma, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, soft tissue cancer, renal cancer, osteosarcoma, mesothelioma, myeloma multiple, bladder carcinoma and esophagcal cancer as well as the use of these pharmaceutical compositions for the treatment of said metastases and cancers. Another aspect of this invention are new antisense oligonucleotides inhibiting the formation of human interleukin 10 and their synthesis. A further aspect of this invention is the use IL-10 antisense oligonucleotides for the preparation of pharmaceutical compositions and for the treatment of cancer and metastases.
    Type: Application
    Filed: February 28, 2005
    Publication date: July 5, 2007
    Inventors: Karl-Hermann Schlingensiepen, Relmar Schlingensiepen, Piotr Jachimczak, Gerhard Stauder, Astrid Bischof, Michael Hafner, Tamara Egger
  • Prophylaxis and therapy of diabetes mellitus I with the help of proteolytic enzymes
    Publication number: 20020015698
    Abstract: The present invention relates to the use of proteolytic enzymes for the prophylaxis and/or therapy of type I diabetes mellitus. The proteolytic enzymes are preferably used at the prediabetic stage.
    Type: Application
    Filed: April 16, 2001
    Publication date: February 7, 2002
    Inventors: Karl Ransberger, Gerhard Stauder
  • Treatment of hepatitis C virus infection using a protease and a flavonoid
    Patent number: 6280728
    Abstract: The use of at least one hydrolytic enzyme and at least one flavonoid shows better activity than &agr;-interferon or ribavirin in the treatment of diseases caused by hepatitis C viruses.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: August 28, 2001
    Assignee: Mucos Pharma GmbH & Co.
    Inventors: Gerhard Stauder, Karl Ransberger
  • Use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women with habitual idiopathic abortion in their anamneses
    Patent number: 5505942
    Abstract: The present invention relates to the use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women in need thereof with habitual idiophathic abortion in their anamneses.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: April 9, 1996
    Assignee: Mucos Pharma GmbH & Co.
    Inventors: Karl Ransberger, Friedrich-Wilhelm Dittmar, Rudolf Kunze, Gerhard Stauder
  • Process of using catabolic enzymes for induction of tumor necrosis factor (TNF)
    Patent number: 5223406
    Abstract: Methods for induction of the tumor necrosis factor, TNF, with at least one of the catabolic enzymes pancreatin, bromelain, papain, lipase, amylase, trypsin, and chymotrypsin are provided.
    Type: Grant
    Filed: October 5, 1990
    Date of Patent: June 29, 1993
    Assignee: Mucos Emulsiongesellschaft m.b.H.
    Inventors: Karl Ransberger, Gerhard Stauder
  • Use of catabolic enzymes for controlling the acquired immune deficiency syndrome (AIDS) and its precursors (LAS, ARC)
    Patent number: 5002766
    Abstract: The therapy approaches known so far for the treatment of the acquired immune deficiency syndrome (AIDS) and its precursors (LAS and ARC) and the secondary diseases related thereto such as opportunistic infections and malignant tumours are either directed against the proliferation of the virus in the body or against the pathogenic organisms of the opportunistic infections or they are selected from the known agents against malignant tumours. So far all therapies did not have any significant success.The new use of catabolic enzymes for the therapy of AIDS and its precursors (LAS and ARC) is made available, with which completely unexpected successes can be achieved in the improvement of the condition of the patient.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: March 26, 1991
    Assignee: Mucos Pharma GmbH & Co.
    Inventors: Karl Ransberger, Gerhard Stauder